The DECIDE-CRLM-10 Randomized Controlled Study: Comparison of Chemotherapy Combined With Localized Treatment for Liver Metastases Versus Palliative Chemotherapy Alone in Colorectal Patients With 10 or More Liver Metastases

This clinical trial is exploring treatment options for patients who have colorectal cancer with at least 10 liver metastases. Colorectal cancer often spreads to the liver, and when this happens, it can be challenging to treat effectively. While surgery is a common way to remove cancer from the liver, only a small percentage of patients qualify for such procedures. This study aims to determine if combining surgery or other localized treatments with chemotherapy can improve survival rates over chemotherapy alone for patients who have many liver metastases. This research is important because it might offer new hope and better outcomes for patients who currently have limited treatment options. Participants in the study will first receive chemotherapy to control the cancer in their liver. After achieving disease control, they will be randomly assigned to receive either additional localized treatment, such as surgery, ablation, or stereotactic body radiotherapy (SBRT), or continue with chemotherapy alone. The study will monitor the participants over five years to see if those who receive the localized treatments live longer than those who only receive chemotherapy. This trial hopes to provide new evidence on the effectiveness of combining local interventions with chemotherapy in improving survival rates in patients with numerous liver metastases.